Oxadiazole derivatives as DGAT inhibitors

Details for Australian Patent Application No. 2005315430 (hide)

Owner AstraZeneca AB

Inventors Butlin, Roger John; Birch, Alan Martin; McCoull, William; Plowright, Alleyn; Donald, Craig Samuel; Bowker, Suzanne Saxon; Nowak, Thorsten

Agent Davies Collison Cave

Pub. Number AU-B-2005315430

PCT Pub. Number WO2006/064189

Priority 0520383.1 07.10.05 GB; 0427328.0 14.12.04 GB; 0507403.4 13.04.05 GB

Filing date 9 December 2005

Wipo publication date 22 June 2006

Acceptance publication date 27 May 2010

International Classifications

C07D 271/10 (2006.01) Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms

A61K 31/4245 (2006.01) - Oxadiazoles

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

14 June 2007 PCT application entered the National Phase

  PCT publication WO2006/064189 Priority application(s): WO2006/064189

27 May 2010 Application Accepted

  Published as AU-B-2005315430

23 September 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005315438-Transgenic animals for assessing drug metabolism and toxicity

2005315428-Dispenser comprising electromagnetic locking with a magnet and reed switch